eligibility_summary
Adults ≥18 with unresectable stage IIIB/IIIC/IV NSCLC, HER2+ (mutation/amplification or IHC 1–3+), measurable disease. Cohort I: ≥1 prior systemic line/HER2 TKI, Cohort II: treatment‑naive (relapse >6 mo after adjuvant/CRT allowed). ECOG 0–1, life ≥3 mo, adequate organs/coagulation, contraception/consent. Exclude: current trials, prior HER2 Ab/ADC, recent TCM/immunomodulators/steroids, EGFR‑TKI <2 wks, active bleeding/infections/autoimmune, uncontrolled effusions/critical invasion, recent TE/CV events, active brain mets (stable OK), HBV/HCV/HIV/TB, psych/substance issues, therapeutic anticoagulants, investigator concern.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II trial in China evaluating disitamab vedotin + tislelizumab + bevacizumab for locally advanced/metastatic NSCLC with HER2 mutation/amplification/expression (pretreated and treatment‑naïve). Disitamab vedotin: HER2‑targeted antibody–drug conjugate (anti‑HER2 mAb linked to MMAE), binds HER2 on tumor cells, internalizes, releases MMAE to inhibit microtubules, causing mitotic arrest/apoptosis (possible bystander effect). Tislelizumab: anti‑PD‑1 IgG4 immune‑checkpoint inhibitor, blocks PD‑1 on T cells to restore antitumor immunity. Bevacizumab: anti‑VEGF‑A monoclonal antibody, inhibits tumor angiogenesis and may normalize vasculature. Targeted cells/pathways: HER2 on tumor cells, PD‑1/PD‑L1 axis on T cells/immune cells, VEGF/VEGFR signaling in endothelial cells.